Navigation Links
New synthetic molecules trigger immune response to HIV and prostate cancer
Date:11/5/2009

New Haven, Conn.Researchers at Yale University have developed synthetic molecules capable of enhancing the body's immune response to HIV and HIV-infected cells, as well as to prostate cancer cells. Their findings, published online in the Journal of the American Chemical Society, could lead to novel therapeutic approaches for these diseases.

The molecules called "antibody-recruiting molecule targeting HIV" (ARM-H) and "antibody-recruiting molecule targeting prostate cancer" (ARM-P) work by binding simultaneously to an antibody already present in the bloodstream and to proteins on HIV, HIV-infected cells and cancer cells. By coating these pathogens in antibodies, the molecules flag them as a threat and trigger the body's own immune response. In the case of ARM-H, by binding to proteins on the outside of the virus, they also prevent healthy human cells from being infected.

"Instead of trying to kill the pathogens directly, these molecules manipulate our immune system to do something it wouldn't ordinarily do," said David Spiegel, M.D., assistant professor of chemistry and the corresponding author of both papers.

Because both HIV and cancer have methods for evading the body's immune system, treatments and vaccinations for the two diseases have proven difficult. Current treatment options for HIV and prostate cancer including antiviral drugs, radiation and chemotherapy involve severe side effects and are often ineffective against advanced cases. While there are some antibody drugs available, they are difficult to produce in large quantities and are costly. They also must be injected and are accompanied by severe side effects of their own.

By contrast, the ARM-H and ARM-P molecules, which the team has begun testing in mice, are structurally simple, inexpensive to produce, and could in theory be taken in pill form, Spiegel said. And because they are unlikely to target essential biological processes in the body, the sid
'/>"/>

Contact: Suzanne Taylor Muzzin
suzanne.taylormuzzin@gmail.com
203-432-8555
Yale University
Source:Eurekalert

Page: 1 2

Related biology news :

1. Chloroplast f and m Thioredoxins Discovered in Nonphotosynthetic Tissues
2. Synthetic compound promotes death of lung-cancer cells, tumors
3. Experts from Stevens, Merck, publish joint paper, Biosynthetic Studies of Platensimycin
4. Researchers decode genetics of rare photosynthetic bacteria
5. Researchers decode genetics of rare photosynthetic bacterium
6. Synthetic molecules may be less expensive alternative to therapeutic antibodies, researchers find
7. Berkeley researchers identify photosynthetic dimmer switch
8. Oregano oil works as well as synthetic insecticides to tackle common beetle pest
9. New projects to raise UK profile in synthetic biology
10. Synthetic Biology: funders move to address social and ethical challenges
11. Synthetic cocoa chemical slows growth of tumors in human cell lines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Valencell, a leader in performance biometric data ... industry leaders such as Intel, Jabra, Atlas, and Scosche ... products. These products will be showcased at CES 2015, ... . "Our partners choose PerformTek ... – with the clinical data to back it up," ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced ... India 2015-2019" report to their offering. ... market is the adoption of multimodal biometric systems. ... of an individual for verification and identification purposes. ...
(Date:12/10/2014)... 9, 2014  Wake Forest Baptist Medical Center today announced ... School of Medicine. Funding for this $50 million capital ... will be publicly launched next summer. ... former 60 series R.J. Reynolds Tobacco Company complex, adjacent ... begin immediately with plans to be ready to welcome ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... report on a new way of preventing potentially harmful plasticizers ... migrating from one of the most widely used groups of ... polyvinyl chloride (PVC) plastics that are safer than those now ... say. Their study is in ACS, Macromolecules , a ...
... 2, 2010 -- A hormone responsible for the body,s stress ... in the pancreas, according to JDRF- funded researchers at the ... are the latest advances to underscore the potential for regeneration ... 1 diabetes. The research, which was published ...
... North Carolina State University have developed a "smart coating" that ... off infection. When patients have hip, knee or dental ... reject the implant. But the smart coating developed at NC ... implant. The coating creates a crystalline layer next to the ...
Cached Biology News:JDRF-funded research advances potential for regeneration as a possible cure for type 1 diabetes 2Smart coating opens door to safer hip, knee and dental implants 2
(Date:12/19/2014)... OR and Hershey, PA (PRWEB) December 19, 2014 ... Pink: BJCT), a leading developer and manufacturer of ... entered into an agreement with Immunomic Therapeutics, Inc. ... Biojector®-2000 needle-free injection device with its LAMP™ vaccine ... an option for an exclusive Worldwide license to ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one of ... Nick Maroulis, Pharm.D. to the newly created position of ... this position, Dr. Maroulis will continue to manage the ... our multi-site pharmacies as the company expands. Dr. Maroulis ... time he has served in many different capacities in ...
(Date:12/19/2014)... , Dec. 19, 2014  Roche (SIX: RO, ROG; ... Technologies, Inc. (Bina), a privately held company based ... USA. Bina provides a big data platform for ... (NGS) data. Bina,s proprietary on-market Genomic Management Solution, ... researchers to perform fast and scalable analyses to ...
(Date:12/19/2014)... 19, 2014 Decision Resources Group finds that ... a 12 percent compound annual growth rate through 2023. ... population and the increasing adoption of dental implants. Growing ... will also spur demand for dental biomaterials because they ... periodontal treatments. Other key findings from Decision ...
Breaking Biology Technology:Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Roche acquires Bina Technologies and enters the genomic informatics market 2Roche acquires Bina Technologies and enters the genomic informatics market 3Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3
... , , , SOUTH SAN ... RIGL ) today announced the pricing of an underwritten public offering ... the public of $7.25 per share. All of the shares are ... up to an additional 1,950,000 shares to cover over-allotments, if any. ...
... , HAYWARD, Calif., Sept. 17 Intarcia ... study comparing its proprietary drug candidate ITCA 650 (DUROS continuous delivery of ... upon the successful completion of a 28-day phase 1b study of ITCA ... to evaluate the doses achieving the best results in the phase 1b ...
... DIEGO, Sept. 16 Aethlon Medical, Inc. (OTC Bulletin Board: AEMD), ... San Diego, California, the stockholders re-elected the incumbent four-person Board of ... ratified the appointment of Squar, Milner, Peterson, ... ending March 31, 2010; , approved ...
Cached Biology Technology:Rigel Announces Pricing of Public Offering of 13,000,000 Shares of Common Stock 2Intarcia Therapeutics, Inc. Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes 2Intarcia Therapeutics, Inc. Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes 3Aethlon Medical, Inc. Announces Annual Meeting Results 2Aethlon Medical, Inc. Announces Annual Meeting Results 3
Mouse monoclonal [B314.1 (MAC 387)] to Macrophage L1 protein Calprotectin (rating: ****) ( Abpromise for all tested applications)....
MOUSE ANTI HUMAN CYTOKERATIN 1-8...
Request Info...
... Polyoxyethylene Lauryl Ether 30% ... Kathon Preservative. Surfactant. Clear ... immunohistochemistry is 1 mL ... solution added to 400 ...
Biology Products: